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Abstract
Adverse events (AEs) are common during disease-modifying antirheumatic drug (DMARD) treatment, but their influence on
treatment results is unclear. We studied AEs in relation to disease activity in early rheumatoid arthritis (RA). Ninety-nine patients
started intensive treatment with three conventional synthetic DMARDs (csDMARDs) and oral prednisolone, and were random-
ized to a 6-month induction treatment with infliximab or placebo. All AEs during the first 12 months of treatment were recorded.
We scored each AE based on severity (scale 1–4) and defined the burden of AEs as the sum of these scores. Patients were divided
into tertiles according to the burden of AEs. As outcomes, we assessed 28-joint disease activity score (DAS28) levels and
remission rates at 12 and 24 months. Three hundred thirty-one AEs in 99 patients were reported, and 27 (8%) were categorized
as severe or serious. Mean burden of AEs per patient was 5.4 ± 4.3. Seventy-nine AEs (24%) led to temporary (n = 52) or
permanent (n = 27) csDMARD discontinuation. Of discontinuations, 1, 21, and 57 were detected in the first, second, and third
tertiles, respectively. DAS28 remission rates decreased across tertiles at 12 months (94, 94, and 76%; p for linearity 0.029) and at
24 months (90, 86, and 70%; p for linearity 0.021). Mean DAS28 levels increased across tertiles at 12 months (1.5 ± 1.0, 1.7 ±
0.9, and 1.9 ± 1.2; p for linearity 0.021) and at 24months (1.4 ± 0.8, 1.6 ± 1.0, and 1.9 ± 1.1; p for linearity 0.007). High burden of
AEs is associated with higher disease activity and lower likelihood of remission in early RA.
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Introduction
Early suppression of disease activity with active and consci-
entious use of disease-modifying antirheumatic drugs
(DMARDs) is essential for achieving good outcomes in
rheumatoid arthritis (RA) [1, 2]. However, DMARDs, like
all drugs, may cause adverse events that lead to discontinua-
tion of the medication or reduced drug adherence.
In RA, the two leading causes for drug discontinuation are
inefficacy and adverse events [3–5]. Adverse events are
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carefully monitored in all clinical trials, but previous studies
have not examined their impact on treatment outcomes in
early RA. In this study, we perform a post hoc analysis of
clinical trial data with intensively treated early RA patients
to determine if the cumulative burden of adverse events during
the first year of treatment is associated with disease activity
and remission rates at 1 and 2 years after study initiation.
Materials and methods
Patients
Ninety-nine patients with early, active, and untreated RA ful-
filling the American College of Rheumatology (ACR) 1987
classification criteria were recruited into the NEO-RACo
(New Finnish Rheumatoid Arthritis Combination treatment
strategy) trial that began in 2003. In this multicenter study,
all patients were treated with a combination of methotrexate
(up to 25 mg/week, administered orally or in case of adverse
events subcutaneously) , sulfasalazine (2 g/day),
hydroxychloroquine (35 mg/kg/week), and oral low-dose
prednisolone (7.5 mg/day) for 2 years. In addition, the patients
were randomized to receive infliximab or placebo infusions at
weeks 4, 6, 10, 18, and 26. The patients were assessed clini-
cally 11 times during the first year, and thereafter every
3 months. The treatment was targeted to a modified ACR
remission throughout the study. Medication had to be modi-
fied if remission was not achieved. The patients were required
to use a combination of three conventional synthetic
DMARDs (csDMARDs) at all times.
If an adverse event led to temporary or permanent drug
discontinuation, csDMARD treatment was restarted as soon
as possible. If drug discontinuation was permanent, the
csDMARDs were substituted as follows: methotrexate with
azathioprine, sulfasalazine with ciclosporin, and
hydroxychloroquine with auranofin. Patient selection criteria
of the trial, treatment protocol, and 2-year outcomes have been
presented in detail previously [6].
Burden of adverse events and outcomes
We analyzed all adverse events during the first 12 months of
the study. The treating physicians categorized the events based
on their severity: (1) mild—barely notable with no measures
required; (2) moderate—possible dose changes in study med-
ication; (3) severe—possible temporary or permanent discon-
tinuation of study medication; and (4) serious—any event
leading to death, hospitalization, or causing permanent or sig-
nificant injury. Each adverse event was taken into account
only once. If the same adverse event was reported on multiple
study visits, we used the most severe category reported. The
investigators recategorized the adverse event only if the
patient had been hospitalized, but the treating physician had
not classified the event as serious. We defined the cumulative
burden of adverse events as the sum of scores (from 1 for mild
to 4 for serious events) of all individual events. We assessed
the 28-joint disease activity score (DAS28) and DAS28 remis-
sion rates (DAS28 < 2.6) at 12 and 24 months as outcomes.
Statistical analysis
The data is presented as means with standard deviations (SD)
or as counts with percentages. For analysis, we divided the
patients into tertiles according to the burden of adverse events.
We used Cochran-Armitage test and analysis of variance
(ANOVA) for evaluating the statistical significance of the hy-
pothesis of linearity. In the case of violation of the assump-
tions (e.g., non-normality), a bootstrap-type test was used. We
used generalizing estimating equations (GEE) models with
appropriate distribution and link function for analyzing repeat-
ed measures data. Age, sex, rheumatoid factor, baseline dis-
ease activity, and treatment arm were used as covariates. The
normality of the variables was evaluated using the Shapiro-
Francia W test. STATA 14.1, StataCorp LP (College Station,
TX, USA), statistical software was used for the analyses.
Results
Ninety-nine patients were included in the study. Three hun-
dred thirty-one adverse events were reported during the first
12 months. The mean burden of adverse events per patient
was 5.4 ± 4.3. The patients were divided into tertiles according
to the burden of adverse events. The baseline clinical and
demographic characteristics of the patients by tertiles are
shown in Table 1. Of the baseline characteristics, erythrocyte
sedimentation rate (p = 0.03) and tender joint count (p =
0.001) differed across the tertiles. The range of the burden of
adverse events in the first, second, and third tertiles was 0–2,
3–6, and 7–18, respectively. Thirteen patients in the first tertile
reported no adverse events.
Seventy-nine (24%) of 331 adverse events led to
csDMARD discontinuation. Of the discontinuations, 52
(66%) were temporary and 27 (34%) permanent. The number
of temporary and permanent csDMARD discontinuations and
the number of severe and serious adverse events were the
highest in the third tertile (Table 2). Of the 27 permanent
csDMARD discontinuations, four involved methotrexate,
ten sulfasalazine, and 13 hydroxychloroquine. In addition,
one patient in the infliximab arm and two patients in the pla-
cebo arm discontinued the 6-month induction treatment with
infliximab or placebo due to an adverse event.
The treating physician classified 22 (7%) of the adverse
events as definitely connected to study medication. In 88
(27%) cases, the connection between study medication and
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an adverse event was probable; in 99 (30%) cases, possible;
and in 85 (26%) cases, unlikely. Thirty (9%) adverse events
were classified as unrelated to study medication, and data
were missing for seven events (2%).
At 12 months, the DAS28 remission rates decreased
across the tertiles according to burden of adverse events,
being 94, 94, and 76% in the first, second, and third tertiles,
respectively (p for linearity 0.029; Fig. 1). Similarly, remis-
sion rates by tertiles at 24 months were 90, 86, and 70% (p
for linearity 0.021). Mean DAS28 scores (±SD) in the first,
second, and third tertiles were 1.5 ± 1.0, 1.7 ± 0.9, and 1.9
± 1.2 at 12 months (p for linearity 0.021), and, respectively,
1.4 ± 0.8, 1.6 ± 1.1, and 1.9 ± 1.1 at 24 months (p for
linearity 0.007; Fig. 1). Mean DAS28 change from baseline
was − 4.2, − 3.5, and − 3.8 in the first, second, and third
tertiles at 12 months, and, respectively, − 4.3, − 3.8, and −
3.8 at 24 months.
Discussion
The influence of adverse events on RA remission rates has not
been explored earlier. In the current study, we found that
higher burden of adverse events during the first year of RA
treatment was associated with lower DAS28 remission rates
and higher disease activity at 1 and 2 years of follow-up in
Table 1 Baseline characteristics
of the patients by tertiles of the
burden of adverse events
Characteristic Tertile of adverse event burden p value
I (n = 31) II (n = 35) III (n = 33)
Demographics
Female, n (%) 20 (65) 22 (63) 24 (73) 0.48
Age years, mean (SD) 48 (9) 47 (10) 44 (12) 0.15
Duration of symptoms (months), mean (SD) 4 (3) 4 (2) 4 (2) 0.99
Rheumatoid factor present, n (%) 25 (81) 27 (77) 23 (70) 0.31
Measures of disease activity
DAS28, mean (SD) 5.7 (1.1) 5.2 (1.2) 5.7 (1.2) 0.99
ESR, (mm/h), mean (SD) 41 (22) 30 (22) 29 (20) 0.03
Swollen joints (66 joint count), mean (SD) 16.5 (5.6) 13.3 (5.7) 16.0 (7.7) 0.81
Tender joints (68 joint count), mean (SD) 17.6 (7.7) 17.2 (8.3) 24.8 (12.9) 0.005
Patient’s global assessment (VAS), mean (SD) 46 (24) 49 (29) 52 (24) 0.26
Pain assessment (VAS), mean (SD) 48 (29) 57 (30) 55 (21) 0.29
Physician’s global assessment (VAS), mean (SD) 52 (20) 47 (21) 55 (21) 0.60
Physical function (HAQ), mean (SD) 0.9 (0.6) 1.0 (0.7) 1.1 (0.7) 0.23
Infliximab treatment, n (%) 19 (61) 15 (43) 16 (48) 0.32
p values are for linearity. The range of the burden of adverse events by tertiles I, II, and III was 0–2, 3–6, and 7–18
DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; VAS, Visual Analog Scale; HAQ,
Health Assessment Questionnaire
Table 2 CsDMARD
discontinuations and severity of
adverse events by tertiles of
burden of adverse events
Tertile of AE burden
I (n = 31) II (n = 35) III (n = 33)
Adverse events
Number, n (%a) 21 (6) 111 (34) 199 (60)
Led to csDMARD discontinuation and switch, n (%a) 0 (0) 5 (2) 22 (7)
Led to temporary csDMARD discontinuation, n (%a) 1 (0) 16 (5) 35 (11)
Adverse event severity
Severe 0 2 9
Serious 0 4 12
Moderate 6 39 96
Mild 15 66 82
a Percentage of all adverse events (n = 331)
AE, adverse event; csDMARD, conventional synthetic disease-modifying antirheumatic drug
Clin Rheumatol (2018) 37:1689–1694 1691
intensively treated early RA patients. Although 92% of the
adverse events were mild or moderate, one in four led to
temporary or permanent csDMARD discontinuation. Despite
these discontinuations, differences in clinical outcomes were
small. DAS28 reduction from baseline by tertiles ranged from
3.5 to 4.2 at 12 months, and, respectively, from 3.5 to 4.3 at
24 months. Most patients, 70–90% depending on the tertile,
achieved DAS28 remission at 24 months.
When interpreting our results, it should be taken into ac-
count that the protocol of the current trial, commenced in
2003, is not in line with the latest international RA manage-
ment recommendations, which suggest tapering glucocorti-
coids as soon as clinically feasible [7]. However, as demon-
strated by the high remission rates, the used strategy leads to
excellent results. Further, triple combination of csDMARDs is
still recommended as the initial treatment for RA in Finland,
where excellent results have been achieved also in routine
clinical practice [8, 9].
We found no previous studies that have specifically assessed
the impact of experienced adverse events on RA outcomes.
However, we identified one recent study that focused on medi-
cation persistence in RA patients [10]. In this study, Contreras-
Yanes et al. showed that the length of DMARD discontinuation
periods during the first 4 years of RA treatment was associated
with higher disease activity and increased disability during the
fifth year in a cohort of Mexican early RA patients. The exact
timing of the non-persistence during the follow-up had no im-
pact on the outcomes, which is slightly surprising, as it is known
that RA generally reacts more amenably to early treatment [11].
As we did not study treatment persistence, it is challenging to
compare these results directly with ours. Nonetheless, based on
the relatively high csDMARD discontinuation rates, non-
persistence caused by adverse events was most likely the prima-
ry reason for lower remission rates in the third tertile of adverse
event burden in our study. Additionally, cumulating adverse
events may have influenced csDMARD adherence negatively
leading to further reducedmedication persistence. The impact of
drug discontinuations is accentuated by the fact that it may take
from 2 to 3months to reach the peak effect of a new csDMARD.
Thus, patients with adverse events leading to drug switches
might be undertreated for several months, which decreases the
probability remission. Further, in routine clinical practice, the
impact of drug discontinuations is likely more pronounced due
to less intensive treatment, particularly if monotherapy is used,
lower adherence, and longer control intervals.
We found only minor differences in the baseline characteris-
tics of patients categorized by the burden of adverse events.
Patients who experienced the most adverse events during the
first 12 months had higher tender joint count and lower erythro-
cyte sedimentation rate (ESR) compared with the two other
groups. The discordance of these measures is interesting and
could be caused by higher disease activity or by higher preva-
lence of non-inflammatory joint pain in the third tertile. The latter
seems more likely based on previous studies, which have shown
that RA patients suffering from non-inflammatory pain, like fi-
bromyalgia, have higher DAS28 scores and lower likelihood of
remission due to disproportionately high subjective disease ac-
tivity measures compared to patients with RA alone [12–14].
Few studies have assessed the underlying causes for
DMARD treatment failure in early RA. According to these
studies, mental health seems to be one of the key factors asso-
ciated with both treatment failure and drug discontinuation [15,
16]. Mental health problems can also affect patient-reported out-
comes; depressive symptoms and anxiety have been shown to
increase DAS28 by inflating tender joint count and patient glob-
al assessment values [17]. Further, some patients may also be
more prone to adverse events due to their psychological charac-
teristics, like anxiety or depression, and negative expectations
concerning medications [18]. In our study, the use of a triple
combination of csDMARDs was mandatory, and therefore ad-
verse events led to changes, and not to cessation or failure, of the
drug regimen. However, impaired mental health may have been
one of the drivers of increased adverse event reporting in our
study. Unfortunately, wewere not able to test this hypothesis due
to lack of data on patients’ psychiatric morbidity.
Despite its strengths such as the clinical trial design reducing
the possibility of bias, and the short follow-up intervals, which
enabled obtaining comprehensive adverse event data, our study
also has some limitations. First, the patients were of working
age and very intensively treated and followed. Therefore, our
results may not be generalizable to other settings and
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Fig. 1 Disease activity score assessing 28-joint (DAS28) scores and
remission rates (DAS28 < 2.6) by tertiles of the 12-month burden of
adverse events at 12 and 24 months. p values are for linearity. Adjusted
for age, sex, rheumatoid factor, baseline disease activity, and treatment
arm (infliximab or placebo)
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populations. Second, because of the small study sample, the
number of csDMARD switches remained low. This prevented
us from assessing the effects of permanent discontinuation of
individual csDMARDs, such as methotrexate. Third, we had no
data on the prevalence of non-inflammatory joint pain and fi-
bromyalgia, or psychiatric morbidity in the study population.
We can therefore only speculate that these factors might be
associated with a higher burden of adverse events.
Additionally, nocebo effect, i.e., negative treatment effects
caused by patient’s negative expectations, could explain a part
of the differences in experienced adverse events. However, ex-
ploring the influence of this phenomenon is beyond the scope
of the current study. Finally, we developed a novel method for
measuring the influence of adverse events. Due to the limited
sample size, our results should be confirmed in larger trials.
We conclude that in early RA patients treated with a triple
combination of csDMARDs, the higher burden of adverse
events during the first year of treatment is associated with
reduced remission rates and higher disease activity thereafter.
These reduced remission rates are most likely explained by
reduced DMARD exposure over time caused by adverse
events. In the current study, one third of patients experienced
almost two thirds of adverse events. Future studies should
elucidate factors influencing patients’ adverse event reporting.
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